MetaVia Inc. (MTVA) - Net Assets
Based on the latest financial reports, MetaVia Inc. (MTVA) has net assets worth $6.33 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.77 Million) and total liabilities ($8.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of MetaVia Inc. to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.33 Million |
| % of Total Assets | 42.88% |
| Annual Growth Rate | N/A |
| 5-Year Change | 10.11% |
| 10-Year Change | N/A |
| Growth Volatility | 161.32 |
MetaVia Inc. - Net Assets Trend (2014–2024)
This chart illustrates how MetaVia Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore MTVA total asset value for the complete picture of this company's asset base.
Annual Net Assets for MetaVia Inc. (2014–2024)
The table below shows the annual net assets of MetaVia Inc. from 2014 to 2024. For live valuation and market cap data, see MetaVia Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.93 Million | -52.47% |
| 2023-12-31 | $16.68 Million | -23.29% |
| 2022-12-31 | $21.75 Million | +49.00% |
| 2021-12-31 | $14.60 Million | +102.65% |
| 2020-12-31 | $7.20 Million | -41.40% |
| 2019-12-31 | $12.29 Million | +192.52% |
| 2018-12-31 | $-13.29 Million | -437.12% |
| 2017-12-31 | $3.94 Million | -80.90% |
| 2016-12-31 | $20.63 Million | +266.66% |
| 2015-12-31 | $-12.38 Million | -2231.45% |
| 2014-12-31 | $-531.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to MetaVia Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13527300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.11% |
| Other Components | $143.78 Million | 1812.87% |
| Total Equity | $7.93 Million | 100.00% |
MetaVia Inc. Competitors by Market Cap
The table below lists competitors of MetaVia Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Binect AG
XETRA:MA10
|
$4.78 Million |
|
Star Fashion Culture Holdings Limited
NASDAQ:STFS
|
$4.78 Million |
|
Era Mandiri Cemerlang Tbk PT
JK:IKAN
|
$4.79 Million |
|
Chenghe Acquisition II Co.
NYSE MKT:CHEB
|
$4.79 Million |
|
Enquest Plc
LSE:ENQ
|
$4.76 Million |
|
Smart Equity AG
HM:SE3
|
$4.76 Million |
|
Magic Empire Global Limited
NASDAQ:MEGL
|
$4.75 Million |
|
REGENCY SILVER CORP.
F:ZJ9
|
$4.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MetaVia Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 16,685,000 to 7,931,000, a change of -8,754,000 (-52.5%).
- Net loss of 27,592,000 reduced equity.
- New share issuances of 19,998,000 increased equity.
- Other factors decreased equity by 1,160,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.59 Million | -347.9% |
| Share Issuances | $20.00 Million | +252.15% |
| Other Changes | $-1.16 Million | -14.63% |
| Total Change | $- | -52.47% |
Book Value vs Market Value Analysis
This analysis compares MetaVia Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-3820.14 | $1.44 | x |
| 2015-12-31 | $-89064.75 | $1.44 | x |
| 2016-12-31 | $147371.43 | $1.44 | x |
| 2017-12-31 | $25101.91 | $1.44 | x |
| 2018-12-31 | $-63569.38 | $1.44 | x |
| 2019-12-31 | $6211.22 | $1.44 | x |
| 2020-12-31 | $1172.55 | $1.44 | x |
| 2021-12-31 | $1664.99 | $1.44 | x |
| 2022-12-31 | $743.69 | $1.44 | x |
| 2023-12-31 | $36.19 | $1.44 | x |
| 2024-12-31 | $11.25 | $1.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MetaVia Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -347.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.05x
- Recent ROE (-347.90%) is below the historical average (-190.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-266.90K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.79 Million |
| 2016 | -70.70% | 0.00% | 0.00x | 1.20x | $-16.65 Million |
| 2017 | -847.88% | 0.00% | 0.00x | 4.83x | $-33.81 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.20 Million |
| 2019 | -173.38% | 0.00% | 0.00x | 1.18x | $-22.54 Million |
| 2020 | -412.02% | 0.00% | 0.00x | 1.52x | $-30.40 Million |
| 2021 | -104.71% | 0.00% | 0.00x | 1.15x | $-16.74 Million |
| 2022 | -64.22% | 0.00% | 0.00x | 1.54x | $-16.14 Million |
| 2023 | -74.74% | 0.00% | 0.00x | 1.37x | $-14.14 Million |
| 2024 | -347.90% | 0.00% | 0.00x | 2.05x | $-28.39 Million |
Industry Comparison
This section compares MetaVia Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MetaVia Inc. (MTVA) | $6.33 Million | 0.00% | 1.33x | $4.77 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed… Read more